Tablet: Each tablet contains Sucralfate 500 mg.
Suspension: Each 5 mL contains Sucralfate 500 mg.
Pharmacology: Sucralfate is a complex formed from sucrose octasulphate and polyaluminum hydroxide.
Its anti-ulcer activity is the result of ulcer-adherent protein-Sucralfate complex that covers the ulcer site and protects it against further attack of acid, pepsin and bile salts.
Sucralfate may promote the healing of peptic ulcers in 3 ways: 1. Forming a chemical complex that binds to the ulcer site to establish a protective barrier.
2. Directly inhibits the actions of acid, pepsin and bile.
3. Blocking the diffusion of gastric acid through the barrier of Sucralfate-albumin.
Sucralfate remains in the Gl tract for extended periods, prolonging the therapeutic actions of the drug.
Furthermore, Sucralfate is minimally absorbed from the GI tract which results in significant systemic side effects.
Short-term treatment (up to 8 weeks) of duodenal ulcer.
Adults: Tablet: 1 tablet four times a day, on empty stomach (1 hour before meal and before bedtime).
Suspension: 2 measurement spoonful (10 mL), four times a day, on empty stomach (1 hour before meal and before bedtime).
SHAKE WELL BEFORE USE.
USE WITHIN 4 MONTHS AFTER OPENING.
Patients who are hypersensitive to this drug.
Sucralfate should be administered with caution in renal failure and dialysis patients.
If required, antacids may be administered ½ hour before or after Sucralfate administration.
Use in Pregnancy & Lactation: See USE IN PREGNANCY & LACTATION section for further information.
Use in Children: Safety and effectiveness in children have not been established.
Sucralfate should only be used during pregnancy if clearly needed.
Sucralfate should be administered with caution in lactating women.
Adverse reactions to Sucralfate were minor and only rarely led to discontinuation of the drug. Constipation and dryness of mouth were the more frequent complaint.
Other adverse reactions were diarrhea, nausea, vomiting, gastric discomfort, flatulence, pruritus, skin rash, sleepiness, vertigo, back pain and headache.
Sucralfate may reduce the extent of absorption or bioavailability of cimetidine, ciprofloxacin, digoxin, ketoconazole, norfloxacin, phenytoin, ranitidine, tetracycline and theophylline. Patients should be advised to take these drugs 2 hours before Sucralfate.
A02BX02 - sucralfate ; Belongs to the class of other drugs used in the treatment of peptic ulcer and gastro-oesophageal reflux disease (GERD).
Eficap susp 500 mg/5 mL
100 mL x 1's (Rp48,600/boks)
Eficap tab 500 mg
10 × 10's (Rp115,000/boks)
Sign Out
